4//SEC Filing
Chang David D 4
Accession 0001737287-25-000004
CIK 0001737287other
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 8:10 PM ET
Size
316.2 KB
Accession
0001737287-25-000004
Insider Transaction Report
Form 4
Chang David D
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to buy)
2025-01-24+1,952,130→ 1,952,130 totalExercise: $1.94Exp: 2035-01-24→ Common Stock (1,952,130 underlying) - Award
Common Stock
2025-01-24+552,174→ 5,363,240 total
Holdings
- 856,044(indirect: See footnote)
Common Stock
- 856,044(indirect: See footnote)
Common Stock
- 1,201,108(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Includes 960 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program.
- [F2]Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
- [F3]Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
- [F4]Securities held in the name of the Chang 2006 Family Trust
- [F5]25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Issuer
Allogene Therapeutics, Inc.
CIK 0001737287
Entity typeother
Related Parties
1- filerCIK 0001611024
Filing Metadata
- Form type
- 4
- Filed
- Jan 27, 7:00 PM ET
- Accepted
- Jan 28, 8:10 PM ET
- Size
- 316.2 KB